{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T08:44:07Z","timestamp":1787215447120,"version":"build-2736575974"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Biomaterialia"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.actbio.2024.12.055","type":"journal-article","created":{"date-parts":[[2024,12,25]],"date-time":"2024-12-25T16:11:09Z","timestamp":1735143069000},"page":"498-513","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["A prodrug nanodevice co-delivering docetaxel and ROR1 siRNA for enhanced triple negative breast cancer therapy"],"prefix":"10.1016","volume":"193","author":[{"given":"Lixuan","family":"Yin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zirang","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengmeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xujie","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiyue","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolong","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongyan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiazhen","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyue","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiran","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengwei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanchao","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0136-3132","authenticated-orcid":false,"given":"Tianqun","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.actbio.2024.12.055_bib0001","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jncc.2024.01.006","article-title":"Cancer incidence and mortality in China, 2022","volume":"4","author":"Han","year":"2024","journal-title":"J. Natl. Cancer Cent."},{"issue":"2","key":"10.1016\/j.actbio.2024.12.055_bib0002","first-page":"3","article-title":"Highlights of recent cancer research","volume":"1","author":"Dong","year":"2022","journal-title":"Holist Integ. Oncol."},{"key":"10.1016\/j.actbio.2024.12.055_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115706","article-title":"Suppression of Ah Receptor (AhR) increases the aggressiveness of TNBC cells and 11-Cl-BBQ-activated AhR inhibits their growth","volume":"215","author":"Elson","year":"2023","journal-title":"Biochem. Pharmacol."},{"issue":"5","key":"10.1016\/j.actbio.2024.12.055_bib0004","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1021\/acs.molpharmaceut.2c01107","article-title":"Reduction-Responsive docetaxel prodrug encapsulated within human serum albumin nanoparticles for cancer therapy","volume":"20","author":"Zhang","year":"2023","journal-title":"Mol. Pharm."},{"issue":"13","key":"10.1016\/j.actbio.2024.12.055_bib0005","doi-asserted-by":"crossref","first-page":"14905","DOI":"10.1021\/acsami.0c01069","article-title":"\u03b1(3)\u03b2(1) integrin-targeting polymersomal docetaxel as an advanced nanotherapeutic for nonsmall cell lung cancer treatment","volume":"12","author":"Zou","year":"2020","journal-title":"ACS. Appl. Mater. Interfaces"},{"key":"10.1016\/j.actbio.2024.12.055_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2019.118699","article-title":"Nanoparticles from Gantrez\u00ae AN-poly(ethylene glycol) conjugates as carriers for oral delivery of docetaxel","volume":"571","author":"Ruiz-Gat\u00f3n","year":"2019","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.actbio.2024.12.055_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106484","article-title":"Design, synthesis, and biological evaluation of 6-(imidazo[1,2-a] pyridin-6-yl) quinazolin-4(3H)-one derivatives as potent anticancer agents by dual targeting Aurora kinase and ROR1","volume":"135","author":"Fan","year":"2023","journal-title":"Bioorg. Chem."},{"issue":"1","key":"10.1016\/j.actbio.2024.12.055_bib0008","doi-asserted-by":"crossref","first-page":"142","DOI":"10.3390\/cells10010142","article-title":"The WNT\/ROR pathway in cancer: from signaling to therapeutic intervention","volume":"10","author":"Menck","year":"2021","journal-title":"Cells"},{"issue":"12","key":"10.1016\/j.actbio.2024.12.055_bib0009","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1158\/1078-0432.CCR-16-2083","article-title":"Analysis of ROR1 protein expression in human cancer and normal tissues","volume":"23","author":"Balakrishnan","year":"2017","journal-title":"Clinic. Cancer Res."},{"issue":"6","key":"10.1016\/j.actbio.2024.12.055_bib0010","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/gtc.13115","article-title":"Role of Wnt5b-Ror1 signaling in the proliferation of pancreatic ductal adenocarcinoma cells","volume":"29","author":"Yamauchi","year":"2024","journal-title":"Genes. Cells"},{"issue":"14","key":"10.1016\/j.actbio.2024.12.055_bib0011","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2022112614","article-title":"YAP\/BRD4-controlled ROR1 promotes tumor-initiating cells and hyperproliferation in pancreatic cancer","volume":"42","author":"Yamazaki","year":"2023","journal-title":"EMBO J."},{"issue":"4","key":"10.1016\/j.actbio.2024.12.055_bib0012","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1073\/pnas.1816262116","article-title":"Inhibition of chemotherapy resistant breast cancer stem cells by a ROR1 specific antibody","volume":"116","author":"Zhang","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.actbio.2024.12.055_bib0013","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ebiom.2019.04.061","article-title":"Antibody-drug conjugate T-DM1 treatment for HER2+ breast cancer induces ROR1 and confers resistance through activation of Hippo transcriptional coactivator YAP1","volume":"43","author":"Islam","year":"2019","journal-title":"EBioMedicine"},{"issue":"6","key":"10.1016\/j.actbio.2024.12.055_bib0014","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1038\/s41375-022-01543-y","article-title":"High expression level of ROR1 and ROR1-signaling associates with venetoclax resistance in chronic lymphocytic leukemia","volume":"36","author":"Ghia","year":"2022","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.actbio.2024.12.055_bib0015","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/nrd.2018.93","article-title":"Principles for targeting RNA with drug-like small molecules","volume":"17","author":"Warner","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"issue":"7","key":"10.1016\/j.actbio.2024.12.055_bib0016","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.1038\/s44319-024-00148-z","article-title":"Functional canonical RNAi in mice expressing a truncated Dicer isoform and long dsRNA","volume":"25","author":"Buccheri","year":"2024","journal-title":"EMBo Rep."},{"issue":"49","key":"10.1016\/j.actbio.2024.12.055_bib0017","doi-asserted-by":"crossref","DOI":"10.1002\/adma.201903637","article-title":"Rekindling RNAi therapy: materials design requirements for in vivo siRNA delivery","volume":"31","author":"Kim","year":"2019","journal-title":"Adv. Mater."},{"key":"10.1016\/j.actbio.2024.12.055_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2022.121803","article-title":"Self-immolative polyprodrug-based tumor-specific cascade amplificated drug release nanosystem for orchestrated synergistic cancer therapy","volume":"289","author":"Wang","year":"2022","journal-title":"Biomaterials"},{"key":"10.1016\/j.actbio.2024.12.055_bib0019","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.2147\/IJN.S258316","article-title":"A novel targeted therapy system for cervical cancer: co-delivery system of antisense LncRNA of MDC1 and oxaliplatin magnetic thermosensitive cationic liposome drug carrier","volume":"16","author":"Ye","year":"2021","journal-title":"Int. J. Nanomedicine"},{"issue":"1","key":"10.1016\/j.actbio.2024.12.055_bib0020","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s11671-021-03626-8","article-title":"Biocompatible FePO(4) nanoparticles: drug delivery, RNA stabilization, and functional activity","volume":"16","author":"Rayamajhi","year":"2021","journal-title":"Nanoscale Res. Lett."},{"key":"10.1016\/j.actbio.2024.12.055_bib0021","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.jconrel.2020.02.038","article-title":"Self-assembly of oxidation-responsive polyethylene glycol-paclitaxel prodrug for cancer chemotherapy","volume":"321","author":"Dong","year":"2020","journal-title":"J. Control Release"},{"issue":"2","key":"10.1016\/j.actbio.2024.12.055_bib0022","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s13233-023-00218-6","article-title":"Dual stimuli-responsive polymeric prodrug consisting of reversible covalent bonded celastrol for tumor targeted delivery","volume":"32","author":"Su","year":"2024","journal-title":"Macromol. Res."},{"key":"10.1016\/j.actbio.2024.12.055_bib0023","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.jconrel.2023.05.015","article-title":"Cascade-amplified self-immolative polymeric prodrug for cancer therapy by disrupting redox homeostasis","volume":"358","author":"Dey","year":"2023","journal-title":"J. Control Release"},{"issue":"20","key":"10.1016\/j.actbio.2024.12.055_bib0024","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202001853","article-title":"Polymeric nanoparticles with ROS-responsive prodrug and platinum nanozyme for enhanced chemophotodynamic therapy of colon cancer","volume":"7","author":"Hao","year":"2020","journal-title":"Adv. Sci."},{"key":"10.1016\/j.actbio.2024.12.055_bib0025","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.jconrel.2022.06.004","article-title":"Taxanes prodrug-based nanomedicines for cancer therapy","volume":"348","author":"Sun","year":"2022","journal-title":"J. Control Release"},{"key":"10.1016\/j.actbio.2024.12.055_bib0026","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.jconrel.2023.07.019","article-title":"Overcoming the blood-brain barrier? - prediction of blood-brain permeability of hydrophobically modified polyethylenimine polyplexes for siRNA delivery into the brain with in vitro and in vivo models","volume":"360","author":"Hartl","year":"2023","journal-title":"J. Control Release"},{"issue":"7","key":"10.1016\/j.actbio.2024.12.055_bib0027","doi-asserted-by":"crossref","first-page":"8012","DOI":"10.1021\/acsnano.9b10219","article-title":"Lysosomal proton buffering of poly(ethylenimine) measured in situ by fluorescent pH-sensor microcapsules","volume":"14","author":"Roy","year":"2020","journal-title":"ACS. Nano"},{"issue":"9","key":"10.1016\/j.actbio.2024.12.055_bib0028","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.4014\/jmb.2207.07058","article-title":"Different influences of biotinylation and pegylation on cationic and anionic proteins for spheroid penetration and intracellular uptake to cancer cells","volume":"32","author":"Jung","year":"2022","journal-title":"J. Microbiol. Biotechnol."},{"issue":"5","key":"10.1016\/j.actbio.2024.12.055_bib0029","doi-asserted-by":"crossref","DOI":"10.1002\/EXP.20230037","article-title":"Deformable nanocarriers for enhanced drug delivery and cancer therapy","volume":"4","author":"Cao","year":"2024","journal-title":"Exploration"},{"issue":"2","key":"10.1016\/j.actbio.2024.12.055_bib0030","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1080\/1354750X.2017.1334152","article-title":"Plasma alpha-1-acid glycoprotein as a potential predictive biomarker for non-haematological adverse events of docetaxel in breast cancer patients","volume":"23","author":"Jabir","year":"2018","journal-title":"Biomarkers"},{"issue":"1","key":"10.1016\/j.actbio.2024.12.055_bib0031","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1186\/s13046-023-02928-2","article-title":"RGCC-mediated PLK1 activity drives breast cancer lung metastasis by phosphorylating AMPK\u03b12 to activate oxidative phosphorylation and fatty acid oxidation","volume":"42","author":"Cheng","year":"2023","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.actbio.2024.12.055_bib0032","doi-asserted-by":"crossref","unstructured":"T.R. Nayak, A. Chrastina, J. Valencia, O. Cordova-Robles, R. Yedidsion, T. Buss, B. Cederstrom, J. Koziol, M.D. Levin, B. Olenyuk, J.E. Schnitzer, Rapid precision targeting of nanoparticles to lung via caveolae pumping system in endothelium, Nature nanotechnology. Advanced online publication, https:\/\/doi.org\/10.1038\/s41565-024-01786-z.","DOI":"10.1038\/s41565-024-01786-z"},{"issue":"5","key":"10.1016\/j.actbio.2024.12.055_bib0033","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1007\/s00210-023-02781-2","article-title":"Effects of chemotherapy on the immune system: implications for cancer treatment and patient outcomes","volume":"397","author":"Sharma","year":"2024","journal-title":"Naunyn. Schmiedebergs. Arch. Pharmacol."}],"container-title":["Acta Biomaterialia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1742706124007761?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1742706124007761?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T03:07:20Z","timestamp":1740625640000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1742706124007761"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":33,"alternative-id":["S1742706124007761"],"URL":"https:\/\/doi.org\/10.1016\/j.actbio.2024.12.055","relation":{},"ISSN":["1742-7061"],"issn-type":[{"value":"1742-7061","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A prodrug nanodevice co-delivering docetaxel and ROR1 siRNA for enhanced triple negative breast cancer therapy","name":"articletitle","label":"Article Title"},{"value":"Acta Biomaterialia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.actbio.2024.12.055","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Acta Materialia Inc. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}